Xoma Corp. bought the U.S. rights to the hypertension drug Aceon — sold as a low-cost generic since 2009 — and up to three late-stage drug candidates that combine Aceon with other active ingredients, the Berkeley company said Tuesday.
Xoma (NASDAQ: XOMA) paid $1.5 million upfront in third-quarter 2010 to acquire the license from French drug maker Les Laboratoires Servier, it said in a Securities and Exchange Commission filing Tuesday.
No comments:
Post a Comment